CD8A and cutaneous melanoma: Our data extend this result to survival outcomes and propose using the eTILs in the clinic, which measures lymphocytes, including CD8+ cells and other subtypes,37 as a predictive factor for response to anti-PD-1-based immunotherapy and survival of advanced cutaneous melanoma patients.